tbuckley/cabot-search huggingface dataset:
Abstract A36: The cytolytic and anti-leukemic potential of ex vivo differentiated NK cells is confined in the CD94 positive population
Authors: Salem Chouaib, Nadine Saleh Khalifé, Meriem Hasmim, Yanyan Zhang, Manale Doldur, Jean Henri Bouhris, Fawzia Louache
Journal: Cancer Research (2017)

Abstract Adoptive transfer of allogeneic natural killer (NK) cells represents a promising treatment approach against acute myeloid leukemia (AML). We developed a cytokine-based culture method for the generation of NK cells derived from CD34+hematopoietic progenitor cells (HPC) isolated from fresh umbilical cord blood (UCB). Immuno-phenotyping of ex vivo expanded NK cells showed typical inhibitory and activating NK receptors except for CD16 and the KIR receptors. CB-derived NK cells displayed good cytolytic activity and phenotypic analysis showed that the lytic potential of these ex vivo differentiated NK was associated with their expression level of CD94. We further characterized UCB-derived NK cells by investigating in vivo their toxicity, biodistribution, and anti-leukemic potential. For this purpose, immune deficient mice were engrafted with a patient derived AML strain. We showed that in vivo only the CD94+ NK cells survive and form conjugate with leukemic blasts. The characterization of CD94+ cells and the involvement of CD94 and its ligand in the regulation of these ex vivo differentiated allogenic NK cells lytic activity will be discussed. Our findings suggest that CD94+ NK selection could be a pertinent approach to select highly functional expanded NK cells before therapeutic use. Citation Format: Salem Chouaib, Nadine Saleh Khalifé, Meriem Hasmim, Yanyan Zhang, Manale Doldur, Jean Henri Bouhris, Fawzia Louache. The cytolytic and anti-leukemic potential of ex vivo differentiated NK cells is confined in the CD94 positive population [abstract]. In: Proceedings of the AACR International Conference: New Frontiers in Cancer Research; 2017 Jan 18-22; Cape Town, South Africa. Philadelphia (PA): AACR; Cancer Res 2017;77(22 Suppl):Abstract nr A36.
Single-cell analysis of experience-dependent transcriptomic states in the mouse visual cortex
Authors: Sinisa Hrvatin, Daniel R. Hochbaum, M. Aurel Nagy, Marcelo Cicconet, Keiramarie Robertson, Lucas Cheadle, Rapolas Zilionis, Alex Ratner, Rebeca Borges-Monroy, Allon M. Klein, Bernardo L. Sabatini, Michael E. Greenberg
Journal: Nature Neuroscience (2017)
Abstract IA18: Moving towards precision medicine for melanoma
Authors: Richard Marais
Journal: Cancer Research (2017)

Abstract Cutaneous melanoma is a potentially deadly skin cancer that is linked to exposure to ultraviolet radiation (UVR). Rapid advances in genome sequencing approaches have provided enormous insight into the genetics of melanoma, revealing that about half of human melanomas carry activating mutations in the protein kinase BRAF. Drugs that target BRAF, or its downstream signaling component MEK, can extend both progression free and overall survival in BRAF mutant melanoma patients. In parallel, drugs that stimulate the immune system to attack melanomas are effective in 20-50% of patients, and in some cases can even lead to cure. Thus, in the last 6-7 years there has been a paradigm shift in the clinical management of melanoma, but nevertheless, the majority of patients still die of their disease, because despite initial excellent responses to BRAF/MEK drugs, most patients will eventually develop resistance and relapse, and we currently do not have effective biomarkers to stratify patients for the large number of immunotherapies that are being developed. New approaches are therefore needed to stratify melanoma patients to improve clinical outcomes, and to that end we have developed a platform of technologies to guide selection of treatments for individual patients. Next generation sequencing is used to investigate the genetics of tumours with the eventual aim of using selecting the most appropriate drugs for an individual patient. Patient-derived xenografts have been developed from over 100 patients and are used to investigate melanoma biology and the response of individual tumours to hypothesis-driven therapeutic approaches. In cases where tumours are inaccessible, xenografts can sometimes be developed from circulating tumour cells (CDX), allowing the biology of late-stage disease to be investigated. Finally, cell-free tumour DNA (ctDNA) in the blood is used to monitor patient responses to treatments and clinical trials are being designed to use this approach to provide insight into the molecular mechanisms underlying tumour growth, to guide clinical decisions about which drugs to administer and also to guide when to switch treatment from one modality to another. Citation Format: Richard Marais. Moving towards precision medicine for melanoma [abstract]. In: Proceedings of the AACR International Conference: New Frontiers in Cancer Research; 2017 Jan 18-22; Cape Town, South Africa. Philadelphia (PA): AACR; Cancer Res 2017;77(22 Suppl):Abstract nr IA18.
Efficacy of Medicaid for Patients With Cancer in California
Authors: Douglas W. Blayney
Journal: JAMA Oncology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Safety and PK results from a phase Ib study of AL3818 (anlotinib) hydrochloride in subjects with ovarian, cervical, and endometrial cancers.
Authors: Theresa Louise Werner, Esther Kannapel, Judy Chen, Melissa Chen, Adam Louis Cohen
Journal: Journal of Clinical Oncology (2017)

e17071 Background: AL3818 (anlotinib) hydrochloride is a multi-targeted receptor tyrosine kinase inhibitor with potential FGFR inhibition and anti-angiogenesis activity in gynecological cancers. A phase Ib dose verification study was conducted at a single U.S. center to evaluate the safety and tolerability of AL3818 and pharmacokinetic (PK) properties after oral administration of a single dose and at steady state after continuous dosing. The 12 mg dose has been used in multiple clinical trials in China for various indications including NSCLC and sarcoma. Methods: Patients with recurrent or persistent ovarian, cervical, endometrial or other uterine cancers refractory to standard therapies were eligible for enrollment in a 3+3 dose escalation design. The starting dose was 12 mg orally daily for 14 days on and 7 days off. Safety assessments included laboratory evaluations, physical exam, ECOG, vitals, ECG, and adverse events monitoring. Single and multi-dose PK were collected. Results: Three patients (1 with ovarian and 2 with endometrial) were enrolled and completed the initial 21-day safety evaluation period. AL3818 at 12mg/day was found to be safe and well tolerated with no dose-limiting toxicities reported in cycle 1. Only grade 1 and 2 treatment emergent adverse events were noted, including hypertension (htn), oral pain, epistaxis, pain, insomnia, headache, fatigue, tinnitus, sinus tachycardia, anorexia, fatigue, urinary tract infection and urinary frequency. No significant safety concerns were noted. After a single 12 mg dose, the average drug concentration peak time (Tmax) was 10 (4-24) hrs; the average max drug blood concentration (Cmax) was 9.60 (8.47-11.50) ng/mL. After multiple, continuous dosing, the average Tmax was 360 hrs (15 days); average Cmax was 63.80 (52.90-80.30) ng/mL. Because one subject experienced grade 2 htn and one subject experienced grade 3 htn on C2D2, the decision was made that the dose would not be escalated with further cohorts. Conclusions: The recommended phase II dose for AL3818 was determined to be 12 mg daily at 2 wks on/1 wk off regimen. Overall this drug was well tolerated. Blood pressure was manageable with anti-hypertensive medication. Clinical trial information: NCT02558348.
Targeting lymphoma with CD37CAR: A pre-clinical study
Authors: S. Walchli, I.M. Sektioglu, H. Köksal, S.E. Josefsson, A. Faane, K. Huse, H. Holte, G. Kvalheim, E.B. Smeland, J.H. Myklebust, E.M. Inderberg
Journal: Annals of Oncology (2017)
Abstract 18142: Head-to-Head Comparison of the Prognostic Accuracy of Computed Tomography Coronary Angiography and Dobutamine Stress Echocardiography in Patient Undergoing Noncardiac Surgery
Authors: Jong-Hwa Ahn, Young-Hoon Jeong, Jeong Yoon Jang, Jin-Sin Koh, Min Gyu Kang, Jin-Yong Hwang, Jeong Rang Park
Journal: Circulation (2016)

Objectives:  The aim of the study was to compare the prognostic accuracy of dobutamine stress echocardiography (DSE) and computed tomography coronary angiography (CTA) in patients with undergoing intermediate to high risk noncardiac surgery.   Methods:  Between July 2014 and April 2016, 220 patients with more than one clinical risk factor for perioperative cardiovascular events were enrolled prospectively. After exclusions, 208 patients performed both DSE and CTA before intermediate to high risk noncardiac surgery. The estimating perioperative clinical risk was classified according to revised cardiac risk index (RCRI), DSE results were categorized as abnormal response (inducible ischemia, nonviable infarction, or drop in systolic BP ≥20 mmHg during test) or not, and CTA results were assessed using the severity of stenosis (significant stenosis: ≥50% maximal stenosis). Perioperative cardiovascular events were defined as cardiac death, non-fatal myocardial infarction, myocardial injury after noncardiac surgery, pulmonary edema, fatal arrhythmias, and prophylactic revascularization.   Results:  Twenty-six patients (12%) had perioperative cardiac events. RCRI-adjusted regression analyses showed that both abnormal response on DSE, (hazard ratio [HR]: 5.7, 95% confidence interval [CI]: 2.29 to 14.25;  p  ) and presence of significant stenosis (HR: 18.8, 95% CI: 5.27 to 67.42;  p  ) on CTA were independently predictive of perioperative cardiovascular events. When comparing ROC curves of the combination models, although both DSE (C-statistic: 0.787) and CTA (C-statistic: 0.891) improved risk stratification beyond clinical risk factors (C-statistic: 0.719), DSE in addition to CTA (C-statistic: 0.918) did not provide better discrimination than CTA alone.   Conclusions:  In the perioperative risk stratification of patients who were undergoing intermediate to high risk noncardiac surgeries, CTA may have a higher prognostic value compared with DSE.
The case against newborn imitation grows stronger
Authors: Susan S. Jones
Journal: Behavioral and Brain Sciences (2017)

Abstract The claim that human newborns imitate is widely accepted and influential. Yet reliable evidence that newborns match modeled behaviors is limited, and there is no empirically based explanation of how the knowledge that imitation requires could develop before birth. In their target article, Keven &amp; Akins (K&amp;A) contribute important new evidence to an alternative account of newborns' matching that challenges the newborn imitation claim.
Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 ‘CREATE’
Authors: P. Schöffski, A. Wozniak, B. Kasper, S. Aamdal, M.G. Leahy, P. Rutkowski, S. Bauer, H. Gelderblom, A. Italiano, L.H. Lindner, I. Hennig, S. Strauss, B. Zakotnik, A. Anthoney, L. Albiges, J.-Y. Blay, P. Reichardt, J. Sufliarsky, W.T.A. van der Graaf, M. Debiec-Rychter, R. Sciot, T. Van Cann, S. Marréaud, T. Raveloarivahy, S. Collette, S. Stacchiotti
Journal: Annals of Oncology (2017)
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial
Authors: Jeffrey A Jones, Anthony R Mato, William G Wierda, Matthew S Davids, Michael Choi, Bruce D Cheson, Richard R Furman, Nicole Lamanna, Paul M Barr, Lang Zhou, Brenda Chyla, Ahmed Hamed Salem, Maria Verdugo, Rod A Humerickhouse, Jalaja Potluri, Steven Coutre, Jennifer Woyach, John C Byrd
Journal: The Lancet Oncology (2017)
Abstract 18527: Real-world Evaluation of Tthe Cardiovascular Safety of Novel Anti-diabetes Therapies in the UK and USA
Authors: Sanjoy K Paul, John Atherton
Journal: Circulation (2017)

Introduction: Recent randomized controlled trials (RCTs) have evaluated secondary cardiovascular (CV) safety with novel anti-diabetes drugs (ADDs) in patients with long-standing type 2 diabetes (T2...
Monitoring universal health coverage within the Sustainable Development Goals: development and baseline data for an index of essential health services
Authors: Daniel R Hogan, Gretchen A Stevens, Ahmad Reza Hosseinpoor, Ties Boerma
Journal: The Lancet Global Health (2017)

Achieving universal health coverage, including quality essential service coverage and financial protection for all, is target 3.8 of the Sustainable Development Goals (SDG). As a result, an index of essential health service coverage indicators was selected by the UN as SDG indicator 3.8.1. We have developed an index for measuring SDG 3.8.1, describe methods for compiling the index, and report baseline results for 2015.16 tracer indicators were selected for the index, which included four from within each of the categories of reproductive, maternal, newborn, and child health; infectious disease; non-communicable diseases; and service capacity and access. Indicator data for 183 countries were taken from UN agency estimates or databases, supplemented with submissions from national focal points during a WHO country consultation. The index was computed using geometric means, and a subset of tracer indicators were used to summarise inequalities.On average, countries had primary data since 2010 for 72% of the final set of indicators. The median national value for the service coverage index was 65 out of 100 (range 22-86). The index was highly correlated with other summary measures of health, and after controlling for gross national income and mean years of adult education, was associated with 21 additional years of life expectancy over the observed range of country values. Across 52 countries with sufficient data, coverage was 1% to 66% lower among the poorest quintile as compared with the national population. Sensitivity analyses suggested ranks implied by the index are fairly stable across alternative calculation methods.Service coverage within universal health coverage can be measured with an index of tracer indicators. Our universal health coverage service coverage index is simple to compute by use of available country data and can be refined to incorporate relevant indicators as they become available through SDG monitoring.Ministry of Health, Japan, and the Rockefeller Foundation.
Recommendations for a Standardized Pulmonary Function Report. An Official American Thoracic Society Technical Statement
Authors: Bruce H. Culver, Brian L. Graham, Allan L. Coates, Jack Wanger, Cristine E. Berry, Patricia K. Clarke, Teal S. Hallstrand, John L. Hankinson, David A. Kaminsky, Neil R. MacIntyre, Meredith C. McCormack, Margaret Rosenfeld, Sanja Stanojevic, Daniel J. Weiner
Journal: American Journal of Respiratory and Critical Care Medicine (2017)

Section:ChooseTop of pageAbstract <<ContentsOverviewIntroductionMethodsReport Format for Spirome...Selecting and Reporting R...Grading the Quality of Pu...ConclusionsReferencesCITING ARTICLES
Image Gallery: Moth‐eaten alopecia as the only cutaneous symptom of acquired secondary syphilis in a 2‐year‐old boy
Authors: Y. Luo, J. Liu
Journal: British Journal of Dermatology (2017)

Funding sources: none. Conflicts of interest: Supported by the Milstein Medical Asian American Partnership Foundation Research Project Award in Skin Disease Dear Editor, A 2‐year‐old boy presented with a 3‐month history of ‘moth‐eaten’ alopecia on the scalp (a, b). Serological tests showed rapid plasma reagin (RPR; titre 1 : 32) and Treponema pallidum particle agglutination (TPPA) positivity. His parents tested negative for syphilis, but his grandmother demonstrated RPR (1 : 32) and TPPA positivity. His grandmother would chew food in daily meals before feeding it to him, which often happens among people from rural areas or who are poorly educated in China. The boy was diagnosed with acquired syphilis. This is a rare case transmitted via premasticated food; the only symptom was moth‐eaten alopecia.1 2
Welsh opt-out law fails to increase organ donations
Authors: Nigel Hawkes
Journal: BMJ (2017)

Two years after Wales adopted an “opt-out” system for organ donation, there is no evidence that it has increased the rate of transplantations.

A report by the Welsh government has found1 that in the 21 months after the new presumed consent legislation came into effect on 1 December 2015, there were 104 donors, while in the corresponding period before the act there had been 101. The difference is insignificant.

Scotland plans to introduce its own version of the Welsh law, and the Health department in England …
Metabolic re-patterning in COPD airway smooth muscle cells
Authors: Charalambos Michaeloudes, Chih-Hsi Kuo, Gulam Haji, Donna K. Finch, Andrew J. Halayko, Paul Kirkham, Kian Fan Chung, Ian M. Adcock
Journal: European Respiratory Journal (2017)

Chronic obstructive pulmonary disease (COPD) airways are characterised by thickening of airway smooth muscle, partly due to airway smooth muscle cell (ASMC) hyperplasia. Metabolic reprogramming involving increased glycolysis and glutamine catabolism supports the biosynthetic and redox balance required for cellular growth. We examined whether COPD ASMCs show a distinct metabolic phenotype that may contribute to increased growth. We performed an exploratory intracellular metabolic profile analysis of ASMCs from healthy nonsmokers, healthy smokers and COPD patients, under unstimulated or growth conditions of transforming growth factor (TGF)-β and fetal bovine serum (FBS). COPD ASMCs showed impaired energy balance and accumulation of the glycolytic product lactate, glutamine, fatty acids and amino acids compared to controls in unstimulated and growth conditions. Fatty acid oxidation capacity was reduced under unstimulated conditions. TGF-β/FBS-stimulated COPD ASMCs showed restoration of fatty acid oxidation capacity, upregulation of the pentose phosphate pathway product ribose-5-phosphate and of nucleotide biosynthesis intermediates, and increased levels of the glutamine catabolite glutamate. In addition, TGF-β/FBS-stimulated COPD ASMCs showed a higher reduced-to-oxidised glutathione ratio and lower mitochondrial oxidant levels. Inhibition of glycolysis and glutamine depletion attenuated TGF-β/FBS-stimulated growth of COPD ASMCs. Changes in glycolysis, glutamine and fatty acid metabolism may lead to increased biosynthesis and redox balance, supporting COPD ASMC growth.
Association of p53-autoantibodies with TP53 somatic mutational profile detected by next generation sequencing in advanced high-grade ovarian cancer
Authors: M. Garziera, E. Cecchin, J. Polesel, R. Roncato, S. Gagno, E. De Mattia, R. Sorio, S. Scalone, E. Poletto, G. Toffoli
Journal: Annals of Oncology (2017)
The association with cardiovascular disease and type 2 diabetes in adults with atopic dermatitis: a systematic review and meta-analysis
Authors: J.P. Thyssen, A.-S. Halling-Overgaard, Y.M.F. Andersen, G. Gislason, L. Skov, A. Egeberg
Journal: British Journal of Dermatology (2017)

Recent studies examining the association between atopic dermatitis (AD) and cardiovascular disease (CVD) and type 2 diabetes have shown inconsistent results.To carry out a systematic review and meta-analysis that examines the association with cardiovascular disease and type 2 diabetes in adults with AD.We compared the risk of CVD and diabetes for adult patients with and without AD by searching the PubMed, Embase and Web of Science databases. Data extraction was carried out by two independent reviewers. We found a total of 2855 citations, of which 53 were considered relevant based on title and abstract. Overall, 16 publications were included in the qualitative analysis, of which 13 were also included in a quantitative meta-analysis of crude data.No association was observed between AD and unspecified but suspected type 2 diabetes [pooled odds ratio (OR) 1·11; 95% confidence interval (CI) 0·87-1·42], hypertension (pooled OR 1·16; 95% CI 0·98-1·37), stroke (pooled OR 1·15; 95% CI 0·95-1·39) or myocardial infarction (pooled OR 1·14; 95% CI 0·83-1·56), but a positive association was observed with angina pectoris (OR 1·73; 95% CI 1·27-2·37). Meta-analysis of adjusted data gave similar results.While adults with AD in some populations have an increased prevalence of cardiovascular risk factors, such as obesity and smoking, it is unlikely that AD represents an independent and clinically relevant risk factor for cardiometabolic disease.
Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network
Authors: Sietse M. Aukema, Eva Hoster, Andreas Rosenwald, Danielle Canoni, Marie-Hélène Delfau-Larue, Grzegorz Rymkiewicz, Christoph Thorns, Sylvia Hartmann, Hanneke Kluin-Nelemans, Olivier Hermine, Martin Dreyling, Wolfram Klapper
Journal: Blood (2017)
Tender Nodules on the Lower Legs
Authors: Liza Karamessinis, Tricia Bhatti, JiaDe Yu
Journal: JAMA Dermatology (2017)

A man in his 20s with panhypopituitarism, septo-optic dysplasia, developmental delay, duodenal stricture, and a history of pancreatitis presented with a painful eruption on both lower legs. What is your diagnosis?
Margaret McCartney: If this was cancer there’d be an outcry—but it’s mental health
Authors: Margaret McCartney
Journal: BMJ (2017)

A million British volunteers will learn skills in mental health first aid, at a cost of £15m. The government, which is funding the exercise, says that this will improve “personal resilience” and “help people recognise and respond effectively to signs of mental illness in others.”

This will include an online learning module “based on what has been shown to work, so that we can all be better at supporting people experiencing poor mental health.” Public Health England will also work with Mental Health First Aid England to build “on the knowledge and experience of the sector.”1

Theresa May has said that she wants to “use the power of government …